Mortality and disease severity among COVID-19 patients receiving renin-angiotensin system inhibitors: a systematic review and meta-analysis

SS Hasan, CS Kow, MA Hadi, STR Zaidi… - American Journal of …, 2020 - Springer
Introduction The use of renin-angiotensin system (RAS) inhibitors, including angiotensin-
converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), was …

Renin–angiotensin-system inhibitors and all-cause mortality in patients with COVID-19: a systematic review and meta-analysis of observational studies

C Bavishi, PK Whelton, G Mancia, G Corrao… - Journal of …, 2021 - journals.lww.com
Aims: We sought to evaluate the association of angiotensin-converting-enzyme inhibitors
(ACEI) or AT1 blockers (ARB) therapy with clinical outcomes in patients with coronavirus …

Effects of renin–angiotensin system inhibitors on mortality and disease severity of COVID-19 patients: a meta-analysis of randomized controlled trials

J Yin, C Wang, X Song, X Li… - American Journal of …, 2022 - academic.oup.com
BACKGROUND There is controversy over the effects of angiotensin-converting enzyme
inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) on the prognosis in patients …

The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis

R Pranata, H Permana, I Huang, MA Lim… - Diabetes & Metabolic …, 2020 - Elsevier
Abstract Background and Aims; To investigate the association between use of angiotensin-
converting enzyme inhibitor (ACEI)/angiotensin-receptor blocker (ARB) and outcomes of …

Mortality and severity in COVID-19 patients on ACEIs and ARBs—a systematic review, meta-analysis, and meta-regression analysis

R Singh, SS Rathore, H Khan, A Bhurwal… - Frontiers in …, 2022 - frontiersin.org
Purpose: The primary objective of this systematic review is to assess association of mortality
in COVID-19 patients on Angiotensin-converting-enzyme inhibitors (ACEIs) and Angiotensin …

Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers and outcomes in patients with COVID-19: a systematic review and meta-analysis

KB Lo, R Bhargav, G Salacup, J Pelayo… - Expert Review of …, 2020 - Taylor & Francis
Background The use of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II
receptor blockers (ARB) in patients with coronavirus disease 2019 (COVID-19) given their …

Renin-angiotensin system antagonists are associated with lower mortality in hypertensive patients with COVID-19

M Megaly, M Glogoza - Scottish Medical Journal, 2020 - journals.sagepub.com
The use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-receptor
blockers (ARBs) in patients with Coronavirus 2019 (COVID-19) has been controversial. We …

Impact of treatment with renin–angiotensin system inhibitors on clinical outcomes in hypertensive patients hospitalized with COVID-19

M Negreira-Caamaño, J Piqueras-Flores… - High Blood Pressure & …, 2020 - Springer
Introduction Concerns have been raised about the possible harmfulness of angiotensin-
converter enzyme inhibitors (ACEi) and aldosterone receptor blockers (ARB) in patients with …

[HTML][HTML] Angiotensin receptor blockers and angiotensin-converting enzyme inhibitors in COVID-19: meta-analysis/meta-regression adjusted for confounding factors

T Lee, A Cau, MP Cheng, A Levin, TC Lee, DC Vinh… - CJC open, 2021 - Elsevier
Abstract Background Angiotensin receptor blockers (ARBs) and/or angiotensin-converting
enzyme (ACE) inhibitors could alter mortality from coronavirus disease 2019 (COVID-19) …

Renin-angiotensin system inhibitors and COVID-19: a systematic review and meta-analysis. Evidence for significant geographical disparities

D Patoulias, A Katsimardou, K Stavropoulos… - Current hypertension …, 2020 - Springer
Abstract Purpose of Review While the COVID-19 pandemic is constantly evolving, it remains
unclear whether the use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin …